Felicitas Hitz
YOU?
Author Swipe
View article: 356 | METABOLIC TUMOR VOLUME IN OLDER PATIENTS WITH ADVANCED‐STAGE CLASSIC HODGKIN LYMPHOMA: RESULTS FROM THE GHSG HD21 TRIAL
356 | METABOLIC TUMOR VOLUME IN OLDER PATIENTS WITH ADVANCED‐STAGE CLASSIC HODGKIN LYMPHOMA: RESULTS FROM THE GHSG HD21 TRIAL Open
View article: 6 | FEASIBILITY OF CTDNA AND PET GUIDED THERAPY IN UNTREATED DLBCL. PRELIMINARY RESULTS OF THE SAKK 38/19 PHASE II TRIAL
6 | FEASIBILITY OF CTDNA AND PET GUIDED THERAPY IN UNTREATED DLBCL. PRELIMINARY RESULTS OF THE SAKK 38/19 PHASE II TRIAL Open
View article: 14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0
14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0 Open
View article: Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update Open
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group conducted the SAKK 35/10 randomized phase 2 trial to compare rituximab (R) alone vs R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL)…
View article: Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature
Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature Open
INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens with…
View article: Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry
Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry Open
AIMS OF THE STUDY: Systemic amyloidoses are rare protein-folding diseases with heterogeneous, often nonspecific clinical presentations. To better understand systemic amyloidoses and to apply state-of-the-art diagnostic pathways and treatme…
View article: SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL
SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL Open
Introduction: Diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable lymphoma. Rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP) is the standard first-line regimen with cure rates nearing…
View article: Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0.
Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0. Open
Introduction: Mature T and NK-cell lymphomas represent a heterogeneous group of rare lymphoid disorders arising from mature T cells of post-thymic origin. The T-cell Project 2.0 (TCP2) was launched in 2018 with the aim of better understand…
View article: SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY
SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY Open
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/14 randomized phase-2 trial (NCT02451111) to evaluate the safety and efficacy of frontline treatment with ibrutinib plus rituxima…
View article: Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0
Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0 Open
Introduction: Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of hematological malignancies with extremely poor prognosis for almost all subtypes. Functional imaging based on 18-fluorodesoxyglucose positron emission tom…
View article: The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network Open
The natural history of limited-stage peripheral T-cell lymphomas (PTCLs) remains poorly defined. We investigated outcomes and prognostic variables in patients registered in the T-Cell Project (TCP) (#NCT01142674) to develop a model to pred…
View article: P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial Open
Background: 18F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MT…
View article: Decision-Making among Experts in Advanced Hodgkin Lymphoma
Decision-Making among Experts in Advanced Hodgkin Lymphoma Open
Introduction: In the treatment of advanced Hodgkin lymphoma (aHL), based on guidelines a multitude of treatment options are available. The availability of PET-guided decision-making and new therapeutic agents increase the complexity of the…
View article: Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial Open
Background 18 F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MT…
View article: S222: MATURE T AND NK CELL LYMPHOMAS CLASSIFIED ACCORDING TO 2016 WHO CLASSIFICATION. A REPORT OF THE INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0.
S222: MATURE T AND NK CELL LYMPHOMAS CLASSIFIED ACCORDING TO 2016 WHO CLASSIFICATION. A REPORT OF THE INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0. Open
Background: Mature T and NK-cell lymphomas represent a heterogeneous group of rare lymphoid disorders arising from mature T cells of post-thymic origin. In 2018 the International T-cell non-Hodgkin’s Lymphoma Study Group launched the T-cel…
View article: SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma Open
This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two DLs of venetoc…
View article: Prognostic Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
Prognostic Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial Open
Background 18 F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the prognostic relevance of metabolic tumor volume (MT…
View article: Genetic and phenotypic attributes of splenic marginal zone lymphoma
Genetic and phenotypic attributes of splenic marginal zone lymphoma Open
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvir…
View article: Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods
Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods Open
Background Multidisciplinary care is pivotal in cancer centres and the interaction of all cancer disease specialists in decision making processes is state‐of‐the‐art. Aim To describe differences of MDTMs by tumour type. Methods Twelve mult…
View article: GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA
GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA Open
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvir…
View article: Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project Open
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 …
View article: Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial Open
The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03 randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules in patients with follicular lymphoma (FL). Here, we report their long-term…
View article: Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial Open
Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Although there are excellent long-term data for intravenou…
View article: Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project Open
The Fondazione Cassa di Risparmio di Modena, the Associazione Angela Serra per la Ricerca sul Cancro, the Fondazione Italiana Linfomi, Allos Therapeutics, Spectrum Pharmaceuticals, Associazione Italiana per la Ricerca sul Cancro, and the N…
View article: Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10) Open
The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide–dexamethasone can overcome lenalidomide resistance in lenal…
View article: Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy Open
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of s…
View article: Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma Open
TO THE EDITOR:
Treatment of proteasome inhibitor (PI)–refractory multiple myeloma (MM) is challenging, with response rates of only 15% to 35% being achieved with next-generation drugs such as pomalidomide, carfilzomib, and daratumumab, al…
View article: Diagnosis and treatment of follicular lymphoma: an update
Diagnosis and treatment of follicular lymphoma: an update Open
Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition to established regimens such as radiother…
View article: IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT
IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT Open
Introduction: Extra-nodal NK/T cell lymphoma (NKTCL) is a distinct clinicopathological entity characterised by a cytotoxic T or NK cell phenotype and invariable Epstein Barr virus (EBV) infection of the malignant clone. An invasive nasal a…
View article: Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma Open